Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00304-8/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz-_iQhRwI3lUHGXDufV0xJLzHZ8fp16ZXPHlPTFDLNdOROrtxzlxcpliXzaCGKIXDGp862pMbAVHg_Y1XnspOSrHIRJTzw&_hsmi=351234214&utm_content=351151133&utm_source=hs_email